BTK and B-cell chronic lymphocytic leukemia: While the PLCG2-mutated leukemia cells were selected for in patients with CLL treated with inhibitors for BTK, the GoF alteration was at same time toxic, thereby resulting in reduced clone sizes compared to non-damaging resistance mutations affecting BTK itself.